System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Eleonora Cocco is an expert in Neurology at University of Cagliari (Italy). As of October 2026, ScienceLeadR ranks Eleonora Cocco in the top 1% of experts worldwide for Multiple Sclerosis and Autoimmune Diseases. Eleonora Cocco has authored 479 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 4 of them ongoing. SLR score: 1,545 (community average: 125). How the SLR is computed.

LeadR Profile

Eleonora Cocco University of Cagliari Italy
1 545 ScienceLeadR Reputation 1545

Unlock

Register Login
Network Map

Neurology

Subspecialties: Immunology - Public Health - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026
Source: PubMed

University of Cagliari

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 479

Citations

Citations: 13 409 1st author: 33 Last author: 82 Unique author: 3

Main journals

Mult Scler 40
Mult Scler Relat Disord 37
J Neurol 36
Neurology 34
Neurol Sci 30

Best Journals

N Engl J Med 2
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Top-Down CSF Peptidomics Reveals Disease-Associated Peptide Signatures and Oxidative Modifications in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.
PMID 42831274 — sclerosis, multiple sclerosis, chromogranins, neuromyelitis optica, demyelinating diseases, therapeutics, proteome		Proteomics20260
Horizon Scanning of Multiple Sclerosis Expenditure in Italy (2025-2029): Updated Insights from the Oracle Model.
PMID 42828703 — sclerosis, multiple sclerosis, therapeutics		Neurol Ther20260
Epigenetic Insights in Pediatric Multiple Sclerosis: DNA Methylation Highlights an Involvement of Epstein-Barr Virus Infection and Host Immune Networks.
PMID 42789917 — environmental exposure, sclerosis, genes, multiple sclerosis, promoter regions, genetic, dna methylation, herpesvirus 4, human, viruses, therapeutics, epstein-barr virus infections, infections, virus diseases		Neurol Neuroimmunol Neuroinflamm20260
Changes in temporal and spatial gait coordination during the six‑minute walk test in people with multiple sclerosis.
PMID 42763819 — sclerosis, multiple sclerosis, computers, gait, walking, walk test		Med Biol Eng Comput20260
Diagnostic value of the kappa free light chain index in multiple sclerosis under the 2024 CSF positivity criterion: a multicentre study in oligoclonal band-negative patients.
PMID 42756799 — sclerosis, multiple sclerosis, oligoclonal bands, diagnosis		Front Immunol20260

Clinical Studies 13

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 7
Phase 3 5
Phase 2 1

By status:

Completed 6
Active not recruiting 2
Recruiting 2
Enrolling by invitation 1
Terminated 1
Unknown 1

By type:

Interventional 11
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 3
multicentric5to9 1
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 9

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to investigate long term safety and tolerability of tolebrutinib in participants with multiple sclerosis
2023-503631-18-01 — sclerosis, multiple sclerosis, safety, nervous system, nervous system diseases, primary progressive multiple sclerosis, secondary progressive multiple sclerosis		Phase 3Active not recruiting2024
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00 — sclerosis, multiple sclerosis, safety, secondary progressive multiple sclerosis		Phase 3Recruiting2026
Non inferiority study of frexalimab subcutaneous administration compared to intravenous administration in adult participants with multiple sclerosis
2024-519304-28-00 — sclerosis, multiple sclerosis, safety, administration, intravenous, pharmacokinetics		Phase 3Recruiting2026
Preventing the Progression of Multiple Sclerosis Early Rehabilitative Treatment and Multimodal Assessment Part A
NCT06219291 — exercise, sclerosis, multiple sclerosis, brain, disease progression, wearable electronic devices, therapeutics, prognosis		N/AEnrolling by invitation2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS